NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
10 trialsNCT06791148 2025-01-24
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT04294784 2024-11-04
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 2 Terminated
NCT03760822 2024-07-08
SOCRATE
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT02486601 2019-02-27
FOXAGAST
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT02229058 2017-07-27
Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
Sun Yat-sen University
Phase 2 Completed
NCT01980810 2016-06-14
GC-A-003
ChineseAMS
Phase 2 Terminated
NCT00661167 2012-01-18
Phase II Study of ABI-007 for Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed